Ass Lorraine Traitement Insuffis Renale
- Address
- Hopitaux De Brabois, Rue Du Morvan, 54500 Vandoeuvre Les Nancy, France
Ass Lorraine Traitement Insuffis Renale - Advanced Kidney Disease & Hematologic Malignancies Research Center
The Association Lorraine Traitement Insuffisance Rénale is a specialized research center focused on advanced therapeutic approaches for patients with severe kidney disease and hematologic malignancies. The center demonstrates particular expertise in managing complex patient populations, including those with advanced chronic kidney disease (stages 4-5) and dialysis-dependent kidney failure, while addressing their elevated cardiovascular risks through innovative anticoagulation strategies.
- Cardiovascular disease management in advanced chronic kidney disease patients, including novel low-dose anticoagulation therapies
- Multiple myeloma treatment optimization using minimal residual disease (MRD)-adapted strategies and novel combination therapies
- AL amyloidosis treatment with innovative immunotherapy combinations targeting hematologic response
- Autologous stem cell transplantation (ASCT) protocols and personalized treatment approaches based on MRD status
The center actively participates in collaborative research networks, particularly through the Intergroupe Francophone du Myélome (IFM), conducting phase 2 and phase 3 clinical trials. Their research portfolio encompasses advanced immunotherapy approaches including isatuximab, teclistamab, and daratumumab for hematologic conditions, alongside groundbreaking studies in nephrology addressing the critical intersection of renal and cardiovascular disease. This dual focus positions the center at the forefront of managing medically complex patients requiring specialized multidisciplinary care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ass Lorraine Traitement Insuffis Renale
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Isatuximab, Pomalidomide, and Dexamethasone Efficacy in AL Amyloidosis Patients Lacking VGPR Post-Therapy | Intergroupe Francophone Du Myelome | Phase II | Not Recruiting | — | Jan 2026 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 2 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.